Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 49, Issue 2, Pages 684-692Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm0508888
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA109542, R01 CA109542-02, R01-CA 109542, R01 CA109542-01A1] Funding Source: Medline
Ask authors/readers for more resources
A screen of indole-based structures revealed the natural product brassinin to be a moderate inhibitor of indoleamine 2,3-dioxygenase (IDO), a new cancer immunosuppression target. A structure-activity study was undertaken to determine which elements of the brassinin structure could be modified to enhance potency. Three important discoveries have been made, which will impact future IDO inhibitor development: (i) The dithiocarbamate portion of the brassinin lead is a crucial moiety, which may be binding to the heme iron of IDO; (ii) an indole ring is not necessary for IDO inhibition; and (iii) substitution of the S-methyl group of brassinin with large aromatic groups provides inhibitors that are three times more potent in vitro than the most commonly used IDO inhibitor, 1-methyl-tryptophan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available